Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

abstract：:Glycosuria is being increasingly recognised as not only a symptom but also as a novel therapeutic approach in the management of type 2 diabetes mellitus (T2DM). This is accomplished through sodium glucose co-transporter 2 (SGLT2) inhibitors. Consequently, the safety and efficacy of these new agents have been thoroughl...

journal_title：Expert opinion on pharmacotherapy

authors： Pafili K,Papanas N

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

journal_title：Expert opinion on pharmacotherapy

authors： Bernstein JA

更新日期：2013-10-01 00:00:00

abstract：:Autism is a heterogeneous condition, currently with no single explanation for all of these findings presented at this conference. What conferences like this offer us, however, are possible courses of new research and the subsequent development of intervention strategies, both orthodox (pharmacological) and perhaps sli...

journal_title：Expert opinion on pharmacotherapy

authors： Whiteley P

更新日期：2001-07-01 00:00:00

abstract：INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

journal_title：Expert opinion on pharmacotherapy

authors： Guarneri V,Dieci MV,Conte P

更新日期：2012-02-01 00:00:00

abstract：:In > 80% of patients with autoimmune hepatitis, steroid therapy alone or in combination with azathioprine results in disease remission. Treatment response results in reversal of fibrosis and excellent long-term survival in many patients, whereas untreated patients may expect a 10-year survival of < 30%. The use of aza...

journal_title：Expert opinion on pharmacotherapy

authors： Heneghan MA,Al-Chalabi T,McFarlane IG

更新日期：2006-02-01 00:00:00

abstract：:The prevalence of obesity has noticeably increased worldwide. The clinician is now frequently facing the challenge of managing patients with concomitant chronic obstructive pulmonary disease (COPD) or asthma and obesity. Obesity is often associated with a poorer control of these chronic respiratory diseases and the op...

journal_title：Expert opinion on pharmacotherapy

authors： Lessard A,Maltais F,Boulet LP

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The eff...

journal_title：Expert opinion on pharmacotherapy

authors： Osman NI,Chapple CR,Cruz F,Desgrandchamps F,Llorente C,Montorsi F

更新日期：2012-10-01 00:00:00

abstract：INTRODUCTION:Status Epilepticus (SE) is the most common neurological emergency of childhood. It requires prompt administration of appropriately selected anti-seizure medications. Areas covered: Following a distinction between estabilished and emergent drugs, we present pharmacological treatment options and their clinic...

journal_title：Expert opinion on pharmacotherapy

authors： Verrotti A,Ambrosi M,Pavone P,Striano P

更新日期：2017-06-01 00:00:00

abstract：OBJECTIVE:Beta-lactamase producing bacteria present a major problem in treating lower respiratory tract infections. The objective of this study was to evaluate efficacy and safety of cefotaxime-sulbactam combination versus amoxicillin-clavulanic acid injection as an alternative therapeutic option for treatment of lower...

journal_title：Expert opinion on pharmacotherapy

authors： Pareek A,Kulkarni M,Daga S,Deshpande A,Chandurkar N

更新日期：2008-11-01 00:00:00

abstract：BACKGROUND:This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation C...

journal_title：Expert opinion on pharmacotherapy

authors： Hosomi Y,Tanai C,Yoh K,Goto Y,Sakai H,Kato T,Kaburagi T,Nishio M,Kim YH,Inoue A,Hasegawa Y,Isobe H,Tomizawa Y,Mori Y,Minato K,Yamada K,Ohashi Y,Kunitoh H

更新日期：2018-07-01 00:00:00

abstract：INTRODUCTION:Stiripentol and vigabatrin are the two anticonvulsant drugs currently approved in severe infantile-onset epilepsies, respectively Dravet syndrome and infantile spasms. AREAS COVERED:For both, the indication was discovered by chance thanks to an exploratory study. Both demonstrated indisputable efficacy th...

journal_title：Expert opinion on pharmacotherapy

authors： Chiron C

更新日期：2016-06-01 00:00:00

abstract：:Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in th...

journal_title：Expert opinion on pharmacotherapy

authors： Ballinger A

更新日期：2000-05-01 00:00:00

abstract：INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

journal_title：Expert opinion on pharmacotherapy

authors： Zwergal A,Strupp M,Brandt T

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

journal_title：Expert opinion on pharmacotherapy

authors： Abdul-Ghani MA,DeFronzo RA

更新日期：2013-08-01 00:00:00

abstract：:The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical ef...

journal_title：Expert opinion on pharmacotherapy

authors： Kwon DS,Mylonakis E

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

journal_title：Expert opinion on pharmacotherapy

authors： Daniels LM,Kufel WD

更新日期：2018-11-01 00:00:00

abstract：:Initially it was considered that moxonidine, like clonidine, acted at central (2)-adrenoceptors to reduce blood pressure. With the characterisation of imidazoline binding sites distinct from (2)-adrenoceptors, the consensus became that moxonidine was acting predominantly at imidazoline I(1) receptors in the rostral ve...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2001-02-01 00:00:00

abstract：:Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 m...

journal_title：Expert opinion on pharmacotherapy

authors： Staresinic AG,Sorkness CA

更新日期：2000-09-01 00:00:00

abstract：:The purine nucleoside analogues, either alone or in combination with other chemotherapeutic agents, are increasingly used in the treatment of patients with indolent B-cell lymphoproliferative disorders. The initial studies in Waldenström's macroglobulinaemia (WM) are very promising. Approximately 40% of patients who h...

journal_title：Expert opinion on pharmacotherapy

authors： Owen RG

更新日期：2001-06-01 00:00:00

abstract：:Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly ...

journal_title：Expert opinion on pharmacotherapy

authors： Marsh S

更新日期：2005-12-01 00:00:00

abstract：BACKGROUND:Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. OBJECTIVE:The clinical literature is summarized with particular focus on randomized controlled studies of apomo...

journal_title：Expert opinion on pharmacotherapy

authors： Gunzler SA

更新日期：2009-04-01 00:00:00

abstract：:Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

journal_title：Expert opinion on pharmacotherapy

authors： Halbreich U,Kahn LS

更新日期：2003-11-01 00:00:00

abstract：:Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...

journal_title：Expert opinion on pharmacotherapy

authors： Foschi M,Lugaresi A

更新日期：2019-08-01 00:00:00

abstract：INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

journal_title：Expert opinion on pharmacotherapy

authors： Yamaoka K,Tanaka Y

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

journal_title：Expert opinion on pharmacotherapy

authors： Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

更新日期：2011-03-01 00:00:00

abstract：:Recognising the value added by economic evaluations of clinical trials and the interaction of clinical, humanistic and economic end points, the Radiation Therapy Oncology Group (RTOG) has developed an Outcomes Model that guides the comprehensive assessment of this triad of end points. This paper will focus on the econ...

journal_title：Expert opinion on pharmacotherapy

authors： Konski A,Watkins-Bruner D,RTOG (Radiation Therapy Oncology Group) Outcomes Model.

更新日期：2004-03-01 00:00:00

abstract：:There has been a significant increase in the number of cases of skin cancer diagnosed in the US in the past few years. Thus, it seems appropriate to review the available compounds that might be used in the chemoprevention of these lesions. This review focuses on the retinoids and details their results in clinical tria...

journal_title：Expert opinion on pharmacotherapy

authors： Niles RM

更新日期：2002-03-01 00:00:00

abstract：INTRODUCTION:In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent. AREAS CO...

journal_title：Expert opinion on pharmacotherapy

authors： Ruxandra U,Antoniu SA,Mihaltan F,Boisteanu D

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

journal_title：Expert opinion on pharmacotherapy

authors： Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

更新日期：2017-04-01 00:00:00

abstract：:The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia. New information continues to emerge on the impact of olanzapine on schizophrenia and on aspects of...

journal_title：Expert opinion on pharmacotherapy

authors： Buckley PF

更新日期：2005-10-01 00:00:00